Aerovate Therapeutics (AVTE) News Today $2.37 -0.02 (-0.84%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 02/21/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest UpdateAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 4,020,000 shares, a growth of 6.9% from the January 15th total of 3,760,000 shares. Based on an average daily trading volume, of 221,800 shares, the short-interest ratio is presently 18.1 days. Approximately 20.5% of the company's shares are short sold.February 17, 2025 | marketbeat.comDeltec Asset Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Deltec Asset Management LLC bought a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 194,124 shares of the company's stock, valuedFebruary 5, 2025 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 35.5% in JanuaryAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 31st total of 1,860,000 shares. Based on an average trading volume of 768,100 shares, the short-interest ratio is currently 3.3 days. Approximately 12.9% of the shares of the stock are sold short.January 30, 2025 | marketbeat.com$TOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - IPG, VTS, AVTE, MHLDJanuary 24, 2025 | markets.businessinsider.comJane Street Group LLC Trims Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Jane Street Group LLC trimmed its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 86.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,805 shares of the company's stock after selliJanuary 17, 2025 | marketbeat.comUnusually active option classes on open January 16thJanuary 16, 2025 | markets.businessinsider.comStock Traders Buy High Volume of Aerovate Therapeutics Call Options (NASDAQ:AVTE)Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Traders bought 3,010 call options on the company. This is an increase of approximately 338% compared to the typical volume of 687 call options.January 16, 2025 | marketbeat.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Rises By 35.5%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 15th total of 1,860,000 shares. Approximately 12.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 768,100 shares, the days-to-cover ratio is presently 3.3 days.January 16, 2025 | marketbeat.comAVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to ShareholdersDecember 28, 2024 | businesswire.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Decreases By 5.3%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,790,000 shares, a decrease of 5.3% from the November 15th total of 1,890,000 shares. Currently, 9.1% of the shares of the stock are sold short. Based on an average trading volume of 765,600 shares, the short-interest ratio is currently 2.3 days.December 17, 2024 | marketbeat.comGSA Capital Partners LLP Purchases 287,163 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)GSA Capital Partners LLP raised its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 226.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 413,795 shares of theNovember 17, 2024 | marketbeat.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 17.3%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 549,800 shares, a decrease of 17.3% from the October 15th total of 665,000 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average daily volume of 750,300 shares, the short-interest ratio is currently 0.7 days.November 15, 2024 | marketbeat.comWedbush Forecasts Higher Earnings for Aerovate TherapeuticsAerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Analysts at Wedbush boosted their FY2024 EPS estimates for Aerovate Therapeutics in a research note issued to investors on Wednesday, November 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($2.85) per share forNovember 15, 2024 | marketbeat.com$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of BMTX, AVTE, ALTR and PFIENovember 13, 2024 | stockhouse.comAerovate Therapeutics Reports Q3 Loss Amid Strategic ShiftNovember 13, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, MPB, AVTE on Behalf of ShareholdersNovember 8, 2024 | stockhouse.comINVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTENovember 5, 2024 | globenewswire.comINVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTENovember 3, 2024 | prnewswire.comTizona’s TTX-080 colorectal cancer trial expands with new armsNovember 3, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of ShareholdersNovember 1, 2024 | prnewswire.comAerovate Therapeutics, Jade Biosciences enter merger agreementOctober 31, 2024 | markets.businessinsider.comAerovate Therapeutics and Jade Biosciences Announce Strategic MergerOctober 31, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Aerovate Therapeutics, Inc. (AVTE)October 31, 2024 | markets.businessinsider.comAerovate Therapeutics and Jade Biosciences Announce Merger AgreementOctober 31, 2024 | markets.businessinsider.comAerovate climbs on all-stock merger deal with JadeOctober 31, 2024 | msn.comShareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersOctober 31, 2024 | businesswire.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 21.4%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 665,000 shares, a decline of 21.4% from the September 30th total of 846,500 shares. Based on an average trading volume of 240,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.4% of the company's stock are sold short.October 28, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 20.9% in SeptemberAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 846,500 shares, a drop of 20.9% from the September 15th total of 1,070,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average daily volume of 284,900 shares, the short-interest ratio is currently 3.0 days.October 13, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Takes Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Deerfield Management Company L.P. Series C acquired a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,411,608 shares of thSeptember 26, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Receives Average Recommendation of "Hold" from AnalystsShares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) have earned a consensus recommendation of "Hold" from the six brokerages that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating. The average twelve-month price objeSeptember 1, 2024 | marketbeat.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Decreases By 6.4%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 842,600 shares, a decrease of 6.4% from the June 30th total of 900,400 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 0.8 days.July 30, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Given Consensus Recommendation of "Hold" by AnalystsShares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) have received an average rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating. The average 1 year price target among brJuly 13, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Up 4.2%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 4.2%July 11, 2024 | marketbeat.comAerovate Therapeutics to Explore Strategic AlternativesJuly 8, 2024 | globenewswire.comInvestigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCJune 21, 2024 | globenewswire.comAerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law FirmJune 20, 2024 | globenewswire.comAerovate Therapeutics (NASDAQ:AVTE) Rating Reiterated by Jefferies Financial GroupJefferies Financial Group reiterated a "hold" rating and issued a $2.00 price target (down from $65.00) on shares of Aerovate Therapeutics in a research report on Monday.June 17, 2024 | marketbeat.comSHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & LevitonJune 17, 2024 | globenewswire.comAerovate Therapeutics (NASDAQ:AVTE) Lowered to Neutral at BTIG ResearchBTIG Research downgraded Aerovate Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday.June 17, 2024 | marketbeat.comAerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionJune 17, 2024 | globenewswire.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 15,000 Shares of StockJune 15, 2024 | insidertrades.comOctagon Capital Advisors LP Lowers Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Octagon Capital Advisors LP lowered its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 403,685 shares of the company's stock after selling 93,685 sharesJune 15, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Up 3.6%Aerovate Therapeutics (NASDAQ:AVTE) Trading Up 3.6%June 13, 2024 | marketbeat.comGreat Point Partners LLC Decreases Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Great Point Partners LLC lowered its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,037,690 shares of the comJune 13, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Down 2% Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 2%June 12, 2024 | marketbeat.comAerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH MarketJune 11, 2024 | seekingalpha.comVestal Point Capital LP Makes New $9.05 Million Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Vestal Point Capital LP acquired a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 400,000 shares of the company's stock, valued at approximatelJune 9, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Down 6.8%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 6.8%June 6, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Stock Rating Reaffirmed by WedbushWedbush restated an "outperform" rating and issued a $41.00 target price on shares of Aerovate Therapeutics in a report on Thursday.June 6, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Up 10.9%Aerovate Therapeutics (NASDAQ:AVTE) Shares Up 10.9%June 5, 2024 | marketbeat.com Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTE Media Mentions By Week AVTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVTE News Sentiment▼1.950.60▲Average Medical News Sentiment AVTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVTE Articles This Week▼12▲AVTE Articles Average Week Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Korro Bio News Today Neumora Therapeutics News Today Y-mAbs Therapeutics News Today Kodiak Sciences News Today Tevogen Bio News Today Neurogene News Today AC Immune News Today Heron Therapeutics News Today Eledon Pharmaceuticals News Today iTeos Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVTE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
